関節リウマチ患者における48週時の治療ゴール達成のウパダシチニブまたはアダリムマブの初期治療としてのインパクト: SELECT-COMPAREの事後解析
Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keac477
Post hoc analysis findings provide the first data evaluating the importance of treatment order with JAKinib vs TNFi as initial therapy, suggesting that a JAKinib first strategy leads to more rapid improvements in treatment outcomes following csDMARD failure.
With a treat-to-target approach showing improvement in both clinical and functional outcomes, Mysler, et al. evaluate the importance of treatment sequencing in SELECT-COMPARE, assessing potential differences between starting upadacitinib or adalimumab therapy following inadequate MTX response.
Keywords:
